Story perspectives

Rapport Therapeutics Shares Soar 200% After Seizure Drug Success

9/9/2025

Summary

Story summary

Rapport Therapeutics (RAPP) shares rose nearly 200% on September 8, 2025, following positive Phase 2a trial results for RAP-219.
The trial demonstrated a 77.8% median reduction in seizures, with 24% of patients achieving complete seizure freedom.
RAP-219 was well-tolerated, showing mild side effects and a low discontinuation rate.
The company plans two Phase 3 trials in Q3 2026 and an FDA meeting in Q4 2025.
Analysts remain cautiously optimistic about RAP-219's market potential.

1 of 1

Story summary

Rapport Therapeutics (RAPP) shares rose nearly 200% on September 8, 2025, following positive Phase 2a trial results for RAP-219.
The trial demonstrated a 77.8% median reduction in seizures, with 24% of patients achieving complete seizure freedom.
RAP-219 was well-tolerated, showing mild side effects and a low discontinuation rate.
The company plans two Phase 3 trials in Q3 2026 and an FDA meeting in Q4 2025.
Analysts remain cautiously optimistic about RAP-219's market potential.